neuroblastoma

Machine learning identifies statin and phenothiazine combo for neuroblastoma treatment

by Erika Svantesson, Lund University edited by Lisa Lock, reviewed by Andrew Zinin  Editors’ notes Credit: EMBO Molecular Medicine (2025). DOI: 10.1038/s44321-025-00349-6 Using machine learning and a large volume of data on genes and existing drugs, researchers at Lund University in Sweden have identified a combination of statins and phenothiazines that is particularly promising in the treatment of the aggressive […]

Machine learning identifies statin and phenothiazine combo for neuroblastoma treatment Read More »

‘Molecular glue’ harnesses the power of the immune system to treat neuroblastoma

by St. Jude Children’s Research Hospital edited by Lisa Lock, reviewed by Robert Egan Models for neuroblastoma cell plasticity and the working mechanism of indisulam. Credit: Nature Communications (2025). DOI: 10.1038/s41467-025-63979-x. https://www.nature.com/articles/s41467-025-63979-x Gene expression governs whether neuroblastoma tumor cells exist in either the adrenergic (differentiated and sensitive to treatment) or mesenchymal (less differentiated and therapy-resistant) cell state. Tumors may switch

‘Molecular glue’ harnesses the power of the immune system to treat neuroblastoma Read More »

GD2 CAR T treatment induces durable remissions in high-risk neuroblastoma

by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan GD2–CART01 toxicities. MRI evidence of the T2/FLAIR alterations observed in two patients that developed grade 3 ICANS (top-left and bottom-left) and their complete resolution (top-right and bottom-right). Credit: Nature Medicine (2025). DOI: 10.1038/s41591-025-03874-6 From Bambino Gesù Children’s Hospital in Rome comes a report that a third-generation CAR T

GD2 CAR T treatment induces durable remissions in high-risk neuroblastoma Read More »

Scroll to Top